Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 12/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497822 | 0.85 | GABRB3 (0.51) | GABRB3GABRA2GABRB2RORCCYP1A2 | |
| SCHEMBL4356417 | 0.77 | MAPK14 (0.37) | CHRM5CHRM3P2RX7 | |
| SCHEMBL1096680 | 0.73 | NR1H4 (0.45) | GABRB3GABRA2GABRB2RORC | |
| SCHEMBL1097054 | 0.72 | NR1H4 (0.42) | — | |
| SCHEMBL498000 | 0.69 | ALDH1A1 (0.44) | GABRB3GABRA2GABRB2KDM4E | |
| SCHEMBL27896017 | 0.69 | NR1H4 (0.43) | GABRB3GABRA2GABRB2RORC | |
| SCHEMBL2255714 | 0.68 | TRPV1 (0.43) | — | |
| SCHEMBL498069 | 0.66 | NR1H4 (0.45) | GABRB3GABRA2GABRB2RORCP2RX7 | |
| SCHEMBL497962 | 0.65 | GABRB3 (0.47) | GABRB3GABRA2GABRB2CYP1A2 | |
| SCHEMBL12188553 | 0.63 | NR1H4 (0.45) | GABRB3GABRA2GABRB2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | GABRB3 448/4885GABRA2 1161/4885GABRB2 473/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | GABRB3 554/4885GABRA2 1309/4885GABRB2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.